Compare
HCW Biologics Inc. vs Altimmune, Inc. vs Clene Inc. vs Scienture Holdings, Inc.
| Latest fiscal year | HCW Biologics Inc. HCWB | Altimmune, Inc. ALT | Clene Inc. CLNN | Scienture Holdings, Inc. SCNX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $54.2K | $41.0K | $200.0K | $431.6K |
| Revenue growth (YoY) | -97.9% | +105.0% | -41.5% | +215.9% |
| Gross margin | 20.0% | n/a | 78.5% (computed) | 76.8% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$7.96M | -$88.09M | -$26.17M | -$41.51M |
| EPS (Diluted) | -$10.63 | -$1.00 | n/a | -$2.70 |
| Operating cash flow | -$13.39M | -$67.53M | -$18.55M | -$13.38M |
| Free cash flow | -$13.39M | -$67.55M | -$18.59M | n/a |
| Cash & equivalents | $1.95M | $43.76M | $5.19M | $6.66M |
| Total assets | $24.52M | $279.93M | $18.13M | $84.18M |
| Total liabilities | $21.76M | $55.04M | $35.72M | $14.06M |
| Shareholders' equity | $2.76M | $224.89M | -$17.59M | $70.12M |
| Return on year-end equity | -287.9% | -39.2% | n/a | -59.2% |
| Shares outstanding | n/a | 110.88M | 10.85M | 40.63M |
Revenue, most recent five fiscal years
| Fiscal year | HCW Biologics Inc. | Altimmune, Inc. | Clene Inc. | Scienture Holdings, Inc. |
|---|---|---|---|---|
| Latest | $54.2K Ended 2025-12-31 | $41.0K Ended 2025-12-31 | $200.0K Ended 2025-12-31 | $431.6K Ended 2025-12-31 |
| 1 year earlier | $2.57M Ended 2024-12-31 | $20.0K Ended 2024-12-31 | $342.0K Ended 2024-12-31 | $136.6K Ended 2024-12-31 |
| 2 years earlier | $2.84M Ended 2023-12-31 | $426.0K Ended 2023-12-31 | $654.0K Ended 2023-12-31 | $1.36M Ended 2023-12-31 |
| 3 years earlier | $6.72M Ended 2022-12-31 | -$68.0K Ended 2022-12-31 | $473.0K Ended 2022-12-31 | $10.25M Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2021-12-31 | $4.41M Ended 2021-12-31 | $723.0K Ended 2021-12-31 | $9.89M Ended 2021-12-31 |